Nxera Pharma Co., Ltd.
Business Highlights and Consolidated Financial Results for the Third Quarter Cumulative Period of the Fiscal Year Ending December 2026 (January–September)
Cumulative January–September revenue was 27,742 million yen, and core operating profit improved to a profit of 9,818 million yen. Increased milestone achievements and expanded partnerships and licenses contributed to revenue. R&D expenses decreased and SG&A expenses were reduced. Cash and cash equivalents decreased to 16,613 million yen. The company will continue to strengthen partnerships and expand in the Asia region.
Key Figures
- Revenue: 27,742 million yen
- Core Operating Profit: Profit of 9,818 million yen
- Cash and Cash Equivalents: 16,613 million yen
- Research and Development Expenses: 8,963 million yen
- Selling, General and Administrative Expenses: 8,333 million yen
AI要約
Overview of Results
Consolidated revenue for the period was 27,742 million yen, contributed by 10 milestone achievements compared with 6 in the previous fiscal year. Core operating profit turned positive at 9,818 million yen, substantially improving from a loss in the prior-year period. R&D expenses decreased to 8,963 million yen, and SG&A expenses were 8,333 million yen, reflecting the impact of cost reductions. Cash and cash equivalents decreased to 16,613 million yen.
Future Strategy and Outlook
The company will continue to expand operations and advance partnerships in Japan and the APAC region. Milestone receipts from partners for assets such as NBI-1117567/NBI-1117569 have contributed to revenue, and expanding licensing and supply agreements in the Asia-Pacific region aims to create long-term value. The company will also continue strengthening its rare disease development pipeline, including the Korean regulatory filing for DMD vamorolone and progress on later-stage pipeline assets and the exercise of options for lucerastat.
Revenue Trend
Operating Profit Trend
Interim Net Income Trend
R&D Expenses Trend
SG&A Expenses Trend
Nxera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
